Insights into the prognostic potential of total alkaline phosphatase in metastatic castration-resistant prostate cancer treated with radium-223

Viani, Gustavo Arruda

doi:10.1590/0100-3984.2023.56.3e2

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article1

Preprint1

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 6 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Increase of prostate-specific antigen doubling time predicts survival in metastatic castration-resistant prostate cancer patients undergoing radium therapy

Lu,

Chiu,

Tsai

2024

Ann Nucl Med

View full text Add to dashboard Cite

Increase of prostate-specific antigen doubling time predicts survival in metastatic castration-resistant prostate cancer patients undergoing radium therapy

Lu,

Chiu,

Tsai

2024

Ann Nucl Med

View full text Add to dashboard Cite

Increase of prostate specific antigen doubling time predicts survival in metastatic castration-resistant prostate cancer patients undergoing [223Ra]RaCl2 therapy

Lu,

Chiu,

Tsai

2023

Preprint

View full text Add to dashboard Cite

Background [223Ra]RaCl2 is an important treatment modality for bone-dominant metastatic castration-resistant prostate cancer (mCRPC). However, there is currently a lack of effective markers to monitor treatment response during the course of treatment. We retrospectively collected data from mCRPC patients who underwent [223Ra]RaCl2 treatment at our institution between August 2020 and June 2023. Prostate specific antigen (PSA) measurements prior to treatment and during treatment were collected. Baseline PSADT was calculated from PSA measurements prior to [223Ra]RaCl2 treatment; interim PSADT was calculated from PSA measurements before [223Ra]RaCl2 treatment and prior to the 4th course injection. Overall survival was calculated from start of treatment to the date of death. Univariable and multivariable analysis using the Cox proportional hazards model were performed to examine the association of factors with overall survival. Results We included 35 patients from our institution, with a median overall survival of 13.3 months. Eighteen (51.4%) completed all six courses of treatment. PSADT response (interim PSADT > baseline PSADT or decreased PSA) was observed in 20 patients. Overall survival was associated with a PSADT response (HR = 0.318, 95% CI 0.133–0.762, p = 0.010) when compared to patients without a PSADT response. Conclusions Dynamic changes in PSADT were associated with survival in mCRPC patients receiving [223Ra]RaCl2 therapy. Comparing interim and baseline PSADT could serve as a valuable marker for determining treatment benefit.

show abstract

Insights into the prognostic potential of total alkaline phosphatase in metastatic castration-resistant prostate cancer treated with radium-223

Cited by 2 publications

References 6 publications

Increase of prostate-specific antigen doubling time predicts survival in metastatic castration-resistant prostate cancer patients undergoing radium therapy

Increase of prostate-specific antigen doubling time predicts survival in metastatic castration-resistant prostate cancer patients undergoing radium therapy

Increase of prostate specific antigen doubling time predicts survival in metastatic castration-resistant prostate cancer patients undergoing [223Ra]RaCl2 therapy

Contact Info

Product

Resources

About